Watson Pharmaceuticals has settled a patent lawsuit with Novartis AG over Watson's generic version of Novartis' Exelon, a treatment for mild or moderate Alzheimer's disease.

Watson Pharmaceuticals has settled a patent lawsuit with Novartis AG over Watson's generic version of Novartis' Exelon, a treatment for mild or moderate Alzheimer's disease. Under the settlement, Novartis granted Watson a license to its U.S. patents covering Exelon. Watson has also agreed that the company will not market its generic equivalent product until sometime prior to the expiration of the patents covering Exelon. The specific date when Watson may launch its generic product and other details concerning the settlement haven't been disclosed, the company said.